黄芪多糖注射液对糖尿病肾病患者尿液CXCL10、E-cadherin及MMP-9水平的影响  

Effects of Astragalus Polysaccharide Injection on the Levels of Urine CXCL10,E-cadherin and MMP-9 in Patients with Diabetic Nephropathy

作　　者：周广举[1] 李宜臻 彭雅茗 杨艳[1] 崔佳乐 吕庆国[2] ZHOU Guang-ju;LI Yi-zhen;PENG Ya-ming;YANG Yan;CUI Jia-le;LYU Qing-guo(Department of Endocrinology,the Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan 637000,China;Department of Endocrinology and Metabolism,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]川北医学院附属医院内分泌科,四川南充637000 [2]四川大学华西医院内分泌代谢科,成都610041

出　　处：《解放军医药杂志》2021年第1期94-97,107,共5页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：四川省科技计划项目(2019YJ0062)。

摘　　要：目的分析黄芪多糖注射液对糖尿病肾病(diabetic nephropathy, DN)患者尿液趋化因子配体10(CXCL10)、E-钙黏蛋白(E-cadherin)及基质金属蛋白酶-9(MMP-9)水平的影响。方法回顾性分析2015年1月—2018年2月收治的80例DN患者临床资料,根据治疗方法分为观察组和对照组,每组40例。对照组给予规范化治疗,观察组在对照组相应治疗基础上辅以黄芪多糖注射液。对比2组血糖、血脂、炎性因子、肾功能及尿液CXCL10、E-cadherin、MMP-9水平,并统计不良反应发生率。结果治疗后2组空腹血糖、糖化血红蛋白、餐后2 h血糖、甘油三酯、总胆固醇、24 h尿白蛋白排泄率、24 h尿蛋白定量、血清肌酐、肌酐清除率、尿素、尿液CXCL10、E-cadherin及MMP-9均较治疗前下降,且观察组低于对照组(P<0.05,P<0.01)。观察组治疗后血清肿瘤坏死因子-α、白介素-6水平低于对照组(P<0.05)。2组治疗期间均未见不良反应。结论黄芪多糖注射液可降低DN患者尿液CXCL10、E-cadherin及MMP-9水平,可通过多途径作用于DN的临床治疗。Objective To analyze the effects of astragalus polysaccharide injection on the levels of urine CXCL10,E-cadherin and matrix metalloproteinase-9(MMP-9)in patients with diabetic nephropathy(DN).Methods The clinical data of 80 patients with DN who were treated in the hospital from January 2015 to February 2018 were retrospectively analyzed.According to different clinical treatments,they were divided into observation group and control group,with 40 cases in each group.Control group was given standardized treatment,and observation group was supplemented with astragalus polysaccharide injection on the basis of the control group.The levels of the blood glucose,blood lipids,inflammatory factors,renal function and urine biochemical indicators such as CXCL10,E-cadherin and MMP-9 were compared between the two groups,and the incidence rate of adverse reactions was recorded.Results After treatment,the levels of fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),postprandial 2 h blood glucose(2 h PG),triglycerides(TG),cholesterol(TC),24 h urinary albumin excretion rate(UAER),24 h urinary protein quantification,serum creatinine(Scr),creatinine clearance rate(CCr),urea nitrogen(BUN),CXCL10,E-cadherin,and MMP-9 were significantly decreased in the two groups(P<0.05),and the levels of them in observation group were lower than those in control group(P<0.05,P<0.01).After treatment,the levels of serum tumour necrosis factor(TNF-α)and interleukin-6(IL-6)in observation group were significantly lower than those in control group(P<0.05).There were no symptoms of any adverse reactions in the two groups during treatment.Conclusion Astragalus polysaccharide injection can reduce the levels of urine CXCL10,E-cadherin and MMP-9 in patients with DN,and can be used in clinical treatment of DN in multiple fashions.

关 键 词：糖尿病肾病 黄芪多糖 趋化因子CXCL10 E-钙黏蛋白 基质金属蛋白酶-9 空腹血糖 甘油三酯 肿瘤坏死因子-α 

分 类 号：R587.24[医药卫生—内分泌]